Opinion on Drug Delivery in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Biotechnology: FDA rule changes could boost generics

The FDA's review of current good manufacturing practice (cGMP) seeks to improve standards of drug manufacture. At the same time, the regulations should reduce confusion over biotech-derived drug products. These changes may open the door to greater use of new manufacturing methods and long term, greater opportunities for biogenerics.

Published By Datamonitor
28 Aug 2002
Expert View
Expert View

Cancer: the generic impact

The cancer market is set for a boom in low cost drugs, as a significant number of high value cancer drugs are set to lose patent protection over the next decade, triggering a dramatic influx of cheaper generic equivalents. But as patients and generics manufacturers bask in the glow, pharmaceutical companies will be forced to gamble on innovation for fear of being left out in the cold?<BR />

Published By Datamonitor
20 Sep 2002
CommentWire
CommentWire

Smallpox vaccination: planning to catch up

In response to the fear of bioterrorism, the US government has given states instructions on how to manage a smallpox outbreak. While the climate of worry over a biological attack has driven vaccine stockpiling - and useful revenues for pharma companies - the necessary strategy and infrastructure lags far behind.

Published By Datamonitor
27 Sep 2002
CommentWire
CommentWire

Barr/AstraZeneca: another tamoxifen stalemate

Although tamoxifen is a generic drug in most countries, it is still protected in the US. Under a 1992 agreement between AstraZeneca and Barr, generic competition should have begun in August - but additional pediatric indications have pushed it back to February 2003. Barr is suing AstraZeneca for the right to produce tamoxifen now; it's not clear who will be the victor.

Published By Datamonitor
10 Oct 2002
Expert View
Expert View

Biogenerics: the threat to protein manufacturers looms large

The therapeutic proteins market is becoming increasingly attractive to generic competitors, which pose a significant threat to the revenue streams of some of the most established classes. As generic manufacturers move in who stands to gain and will existing therapeutic protein manufacturers survive the competition?

Published By Datamonitor
11 Oct 2002
CommentWire
CommentWire

BMS: new Glucovance indication won't end decline

The FDA has approved the use of BMS' glyburide and metformin pill, Glucovance, alongside the TZD class of anti-diabetic medications. TZDs are commonly administered to patients who are not under adequate glycemic control. However, the approval is unlikely to have a significant impact - physicians are prescribing the drugs as a combination already.

Published By Datamonitor
16 Oct 2002
CommentWire
CommentWire

Andrx: down but not out on Prilosec ruling

The Prilosec infringement decision is a heavy short-term blow for Andrx, particularly as KUDCO's version of the drug was ruled acceptable. However, it does not drastically affect the company's long-term prospects, which are based on its expertise in specialty generics. Even without omeprazole, Andrx should still be one of the fastest growing generics companies to 2007.

Published By Datamonitor
16 Oct 2002
CommentWire
CommentWire

AstraZeneca: passing the baton to Arimidex

AstraZeneca's Arimidex is associated with a lower risk of endometrial abnormalities than the UK company's older breast cancer drug, tamoxifen. Tamoxifen generics are expected to flood the US market early next year, hitting AstraZeneca's bottom line, but the news should further enhance Arimidex as a worthy successor to tamoxifen.

Published By Datamonitor
21 Oct 2002
CommentWire
CommentWire

PowderJect: holding out for a hero

Struggling UK vaccines firm PowderJect has turned down an eager offer from US giant Chiron. PowderJect now has to decide whether to try and lift its struggling sales itself, or look for a higher offer - whether from Chiron or other interested parties such as GSK. With plenty of cash, it can certainly afford to wait for a new bid.

Published By Datamonitor
23 Oct 2002
CommentWire
CommentWire

GSK: looking further ahead with Exelixis deal

GSK's partnership with genomics-based drug discovery firm Exelexis is a logical move. The pharma giant has already bolstered its weak late stage pipeline with licensing deals; Exelixis should help do the same for its early stage pipeline. GSK is successfully using its vast financial resources to compensate for the failure of its internal R&D.

Published By Datamonitor
30 Oct 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.